298 related articles for article (PubMed ID: 34930086)
21. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
[TBL] [Abstract][Full Text] [Related]
22. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
23. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
Joppi R; Bertele' V; Garattini S
Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
[TBL] [Abstract][Full Text] [Related]
24. Orphan drug development: The impact of regulatory and reimbursement frameworks.
Huang YJ; Chao WY; Wang CC; Chang LC
Drug Discov Today; 2022 Jun; 27(6):1724-1732. PubMed ID: 35257859
[TBL] [Abstract][Full Text] [Related]
25. Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis.
Chan AYL; Chan VKY; Olsson S; Fan M; Jit M; Gong M; Zhang S; Ge M; Pathadka S; Chung CCY; Chung BHY; Chui CSL; Chan EW; Wong GHY; Lum TY; Wong ICK; Ip P; Li X
Value Health; 2020 Dec; 23(12):1580-1591. PubMed ID: 33248513
[TBL] [Abstract][Full Text] [Related]
26. Determinants of orphan drugs prices in France: a regression analysis.
Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
[TBL] [Abstract][Full Text] [Related]
27. No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot study.
Stolk P; Heemstra HE; Leufkens HG; Bloechl-Daum B; Heerdink ER
Orphanet J Rare Dis; 2009 Dec; 4():27. PubMed ID: 20003427
[TBL] [Abstract][Full Text] [Related]
28. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries.
Kamusheva M; Manova M; Savova AT; Petrova GI; Mitov K; Harsányi A; Kaló Z; Márky K; Kawalec P; Angelovska B; Lakić D; Tesar T; Draganic P; Geitona M; Hatzikou M; Paveliu MS; Männik A
Front Pharmacol; 2018; 9():795. PubMed ID: 30079023
[No Abstract] [Full Text] [Related]
29. Pharmaceutical policy and innovation for rare diseases: A narrative review.
Alonso Ruiz A; Large K; Moon S; Vieira M
F1000Res; 2023; 12():211. PubMed ID: 38778810
[TBL] [Abstract][Full Text] [Related]
30. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
Rawson NSB
J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
[TBL] [Abstract][Full Text] [Related]
31. Orphan drugs for rare diseases: is it time to revisit their special market access status?
Simoens S; Cassiman D; Dooms M; Picavet E
Drugs; 2012 Jul; 72(11):1437-43. PubMed ID: 22747423
[TBL] [Abstract][Full Text] [Related]
32. European regulation on orphan medicinal products: 10 years of experience and future perspectives.
; Westermark K; Holm BB; Söderholm M; Llinares-Garcia J; Rivière F; Aarum S; Butlen-Ducuing F; Tsigkos S; Wilk-Kachlicka A; N'Diamoi C; Borvendég J; Lyons D; Sepodes B; Bloechl-Daum B; Lhoir A; Todorova M; Kkolos I; Kubáčková K; Bosch-Traberg H; Tillmann V; Saano V; Héron E; Elbers R; Siouti M; Eggenhofer J; Salmon P; Clementi M; Krieviņš D; Matulevičiene A; Metz H; Vincenti AC; Voordouw A; Dembowska-Bagińska B; Nunes AC; Saleh FM; Foltánová T; Možina M; Torrent i Farnell J; Beerman B; Mariz S; Evers MP; Greene L; Thorsteinsson S; Gramstad L; Mavris M; Bignami F; Lorence A; Belorgey C
Nat Rev Drug Discov; 2011 May; 10(5):341-9. PubMed ID: 21532564
[TBL] [Abstract][Full Text] [Related]
33. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
Tiwari J
Regul Toxicol Pharmacol; 2015 Feb; 71(1):63-7. PubMed ID: 25497996
[TBL] [Abstract][Full Text] [Related]
34. Critical assessment of belgian reimbursement dossiers of orphan drugs.
Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
[TBL] [Abstract][Full Text] [Related]
35. Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes DA; Tunnage B; Yeo ST
QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
[TBL] [Abstract][Full Text] [Related]
36. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
37. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
38. Trends from two decades of orphan designations in paediatric rare neuromuscular diseases.
Duarte DM; da Silva Lima MB; Sepodes B
J Neurol Sci; 2024 May; 460():122989. PubMed ID: 38581740
[TBL] [Abstract][Full Text] [Related]
39. [Access to medicines for rare diseases: regulatory aspects and public health priorities.].
Costa E; Grimaldi G; Del Grosso V; Isgrò A; Genazzani A
Recenti Prog Med; 2022; 113(7):415-424. PubMed ID: 35852076
[TBL] [Abstract][Full Text] [Related]
40. Do we need authorized orphan drugs when compounded medications are available?
Dooms M; Pincé H; Simoens S
J Clin Pharm Ther; 2013 Feb; 38(1):1-2. PubMed ID: 22973866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
